利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.032 seconds)

    MEDICAL DEVICES CONTAINING RAPAMYCIN ANALOGS
    1.
    发明申请
    MEDICAL DEVICES CONTAINING RAPAMYCIN ANALOGS 审中-公开
    含有RAPAMYCIN类似物的医疗器械

    公开(公告)号：US20160220739A1

    公开(公告)日：2016-08-04

    申请号：US15091473

    申请日：2016-04-05

    Applicant: Abbott Laboratories

    Inventor： Karl W. Mollison ,  Angela M. LeCaptain ,  Sandra E. Burke ,  Keith R. Cromack ,  Peter J. Tarcha ,  Yen-Chih J. Chen ,  John L. Toner

    IPC: A61L31/16 ,  A61L31/14 ,  C07D498/18 ,  A61L31/10

    CPC classification number: A61L31/16 ,  A61L27/34 ,  A61L27/54 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L31/148 ,  A61L2300/41 ,  A61L2300/416 ,  A61L2300/426 ,  A61L2300/604 ,  A61L2300/606 ,  C07D498/18

    Abstract: A medical device comprises a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to drugs of Formula (I). The drugs of Formula (I) can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.

    Abstract translation: 医疗装置包括能够容纳或支撑药学上可接受的载体或赋形剂的支持结构，该载体或赋形剂可以含有一种或多种治疗剂或物质，载体优选在其表面上包括涂层，并且包含 治疗物质，例如药物。 适用于本发明的医疗装置的支撑结构包括但不限于冠状支架，外周支架，导管，动静脉移植物，旁路移植物和用于脉管系统中的药物递送球囊。 适用于本发明的药物包括但不限于式（I）的药物。 式（I）的药物可以与另一种药物组合使用，包括选自抗增殖剂，抗血小板剂，抗炎剂，抗血栓形成剂，细胞毒性药物，抑制细胞因子或趋化因子结合的药物， 细胞去分化抑制剂，抗脂血症药，基质金属蛋白酶抑制剂，细胞抑制药物或这些药物的组合。

    MULTIPLE DRUG DELIVERY FROM A BALLOON AND A PROSTHESIS
    2.
    发明申请
    MULTIPLE DRUG DELIVERY FROM A BALLOON AND A PROSTHESIS 审中-公开
    从气球和PROSTHESIS提供的多种药物

    公开(公告)号：US20150196692A1

    公开(公告)日：2015-07-16

    申请号：US14599215

    申请日：2015-01-16

    Applicant: ABBOTT LABORATORIES

    Inventor： John L. Toner ,  Sandra E. Burke ,  Keith R. Cromack ,  Randolf von Oepen

    IPC: A61L31/16 ,  A61L29/16 ,  A61F2/958 ,  A61M25/10 ,  A61F2/91 ,  A61L31/10 ,  A61L29/08

    CPC classification number: A61L31/16 ,  A61F2/91 ,  A61F2/958 ,  A61F2230/0054 ,  A61F2250/0067 ,  A61F2310/0097 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L2300/606 ,  A61M25/10 ,  A61M2025/105

    Abstract: System for treating vascular disease comprising a balloon having an outer surface for temporary contact with a vessel wall when in an expanded state, a coating disposed on at least a portion of the outer surface, the coating including an initial amount of a cytostatic agent selected from the group consisting of Zotarolimus (ABT578), everolimus, pimecrolimus, and a combination thereof, the coating being capable of maintaining a therapeutically effective amount of the cytostatic agent on the outer surface for delivery to a vessel wall, and further wherein between about 4.9% to about 23% of the initial amount of the cytostatic agent on the outer surface remains disposed on the outer surface after delivery of the therapeutically effective amount of the cytostatic agent to the vessel wall, and optionally, a stent disposed on the balloon.

    Abstract translation: 用于治疗血管疾病的系统，其包括具有外表面的球囊，所述球囊处于膨胀状态时与血管壁暂时接触，涂层设置在所述外表面的至少一部分上，所述涂层包含初始量的细胞生长抑制剂，所述细胞生长抑制剂选自 由佐他莫司（ABT578），依维莫司，吡美莫司及其组合组成的组，该涂层能够在外表面上维持治疗有效量的细胞生长抑制剂以输送到血管壁，此外，其中约4.9％ 在治疗有效量的细胞生长抑制剂递送到血管壁之后，外部表面上的细胞生长抑制剂的初始量的约23％仍然设置在外表面上，并且任选地，设置在气囊上的支架。

    DELIVERY OF HIGHLY LIPOPHILIC AGENTS VIA MEDICAL DEVICES
    5.
    发明申请
    DELIVERY OF HIGHLY LIPOPHILIC AGENTS VIA MEDICAL DEVICES 审中-公开
    通过医疗器械交付高效药物

    公开(公告)号：US20150112425A1

    公开(公告)日：2015-04-23

    申请号：US14588053

    申请日：2014-12-31

    Applicant: Abbott Laboratories

    Inventor： Keith R. Cromack ,  John L. Toner ,  Sandra E. Burke ,  Richard W. Krasula ,  Lewis B. Schwartz

    IPC: A61L31/10 ,  A61F2/82 ,  A61F2/04 ,  A61L31/16

    CPC classification number: A61L31/10 ,  A61F2/04 ,  A61F2/82 ,  A61F2002/044 ,  A61F2002/047 ,  A61F2250/0067 ,  A61L31/16 ,  A61L2300/00 ,  A61L2300/216 ,  A61L2300/222 ,  A61L2300/606

    Abstract: An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

    Abstract translation: 一种用于递送与医疗装置相关联的亲脂剂的装置和系统，包括：医疗装置，能够穿透体腔的第一亲脂性试剂，其中第一亲脂性试剂的转移系数为统计学上显着的 至少约5,000，其中所述第一亲脂性试剂与所述医疗装置相关联，其中所述第一亲脂性试剂/医疗装置放置在所述体腔附近，并且其中治疗有效量的所述第一亲脂性试剂被递送至 课程。 此外，本发明涉及一种用于提高受试者通畅的方法，包括将医疗装置放置在体腔中，用于治疗和/或预防相邻疾病或维持体腔通畅。

    Multiple drug delivery from a balloon and prosthesis
    6.
    发明授权
    Multiple drug delivery from a balloon and prosthesis 有权
    从气球和假体多次给药

    公开(公告)号：US08956639B2

    公开(公告)日：2015-02-17

    申请号：US13935025

    申请日：2013-07-03

    Applicant: Abbott Laboratories

    Inventor： John L. Toner ,  Sandra E. Burke ,  Keith R. Cromack ,  Randolf von Oepen

    IPC: A61F13/00 ,  A61L31/16 ,  A61F2/91 ,  A61F2/958 ,  A61L29/08 ,  A61L29/16 ,  A61L31/10

    CPC classification number: A61L31/16 ,  A61F2/91 ,  A61F2/958 ,  A61F2230/0054 ,  A61F2250/0067 ,  A61F2310/0097 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L2300/606 ,  A61M25/10 ,  A61M2025/105

    Abstract: System for treating vascular disease comprising a balloon having an outer surface for temporary contact with a vessel wall when in an expanded state, a coating disposed on at least a portion of the outer surface, the coating including an initial amount of a cytostatic agent selected from the group consisting of Zotarolimus (ABT578), everolimus, pimecrolimus, and a combination thereof, the coating being capable of maintaining a therapeutically effective amount of the cytostatic agent on the outer surface for delivery to a vessel wall, and further wherein between about 4.9% to about 23% of the initial amount of the cytostatic agent on the outer surface remains disposed on the outer surface after delivery of the therapeutically effective amount of the cytostatic agent to the vessel wall, and optionally, a stent disposed on the balloon.

    Abstract translation: 用于治疗血管疾病的系统，其包括具有外表面的球囊，所述球囊处于膨胀状态时与血管壁暂时接触，涂层设置在所述外表面的至少一部分上，所述涂层包含初始量的细胞生长抑制剂，所述细胞生长抑制剂选自 由佐他莫司（ABT578），依维莫司，吡美莫司及其组合组成的组，该涂层能够在外表面上维持治疗有效量的细胞生长抑制剂以输送到血管壁，此外，其中约4.9％ 在治疗有效量的细胞生长抑制剂递送到血管壁之后，外部表面上的细胞生长抑制剂的初始量的约23％仍然设置在外表面上，并且任选地，设置在气囊上的支架。

    SURFACE INTERACTIONS TO IMPROVE RETENTION OF MEDICAL DEVICES
    7.
    发明申请
    SURFACE INTERACTIONS TO IMPROVE RETENTION OF MEDICAL DEVICES 审中-公开
    表面相互作用改善医疗器械的保留

    公开(公告)号：US20160100967A1

    公开(公告)日：2016-04-14

    申请号：US14968707

    申请日：2015-12-14

    Applicant: Abbott Laboratories

    Inventor： Randolf Von Oepen ,  John L. Toner

    IPC: A61F2/958 ,  A61L31/08

    CPC classification number: A61F2/958 ,  A61F2002/9583 ,  A61L29/085 ,  A61L29/14 ,  A61L31/08 ,  A61L31/10 ,  A61L31/14

    Abstract: A method for improving the retention between the surfaces of medical devices. The method includes coating a surface of one medical device such as a stent with a coating that includes a functional group and coating a surface of another medical device such as a balloon with a coating that includes an identical or different functional group. The method further includes interacting the coated surfaces to produce a plurality of bonds between the surfaces, thereby improving retention.

    Abstract translation: 一种用于改善医疗装置表面之间的保持性的方法。 该方法包括用包括官能团的涂层涂覆诸如支架的一个医疗装置的表面，并用包括相同或不同官能团的涂层涂覆其它医疗装置例如气囊的表面。 该方法还包括相互作用涂覆的表面以在表面之间产生多个键，从而改善保留。

    Multiple Drug Delivery From A Balloon And Prosthesis
    8.
    发明申请
    Multiple Drug Delivery From A Balloon And Prosthesis 有权
    从气球和假体的多个药物递送

    公开(公告)号：US20130297000A1

    公开(公告)日：2013-11-07

    申请号：US13935025

    申请日：2013-07-03

    Applicant: Abbott Laboratories

    Inventor： John L. Toner ,  Sandra E. Burke ,  Keith R. Cromack ,  Randolf von Oepen

    IPC: A61L31/16 ,  A61L29/16

    CPC classification number: A61L31/16 ,  A61F2/91 ,  A61F2/958 ,  A61F2230/0054 ,  A61F2250/0067 ,  A61F2310/0097 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L2300/606 ,  A61M25/10 ,  A61M2025/105

    Abstract: System for treating vascular disease comprising a balloon having an outer surface for temporary contact with a vessel wall when in an expanded state, a coating disposed on at least a portion of the outer surface, the coating including an initial amount of a cytostatic agent selected from the group consisting of Zotarolimus (ABT578), everolimus, pimecrolimus, and a combination thereof, the coating being capable of maintaining a therapeutically effective amount of the cytostatic agent on the outer surface for delivery to a vessel wall, and further wherein between about 4.9% to about 23% of the initial amount of the cytostatic agent on the outer surface remains disposed on the outer surface after delivery of the therapeutically effective amount of the cytostatic agent to the vessel wall, and optionally, a stent disposed on the balloon.

    Abstract translation: 用于治疗血管疾病的系统，其包括具有外表面的球囊，所述球囊处于膨胀状态时与血管壁暂时接触，涂层设置在所述外表面的至少一部分上，所述涂层包含初始量的细胞生长抑制剂，所述细胞生长抑制剂选自 由佐他莫司（ABT578），依维莫司，吡美莫司及其组合组成的组，该涂层能够在外表面上维持治疗有效量的细胞生长抑制剂以输送到血管壁，此外，其中约4.9％ 在治疗有效量的细胞生长抑制剂递送到血管壁之后，外部表面上的细胞生长抑制剂的初始量的约23％仍然设置在外表面上，并且任选地，设置在气囊上的支架。

Patent Agency Ranking